PALO ALTO, Calif., Aug. 8, 2019 /PRNewswire/ -- This afternoon,
Varian (NYSE: VAR) posted a presentation providing an overview of
the recently proposed radiation oncology alternative payment model
and calendar year 2020 rates by the Center for Medicare &
Medicaid Services. To access the web deck, visit the Investor
Relations page on the Varian website at
www.varian.com/investors.
About Varian
At Varian, we envision a world without fear of cancer. For
more than 70 years, we have developed, built and delivered
innovative cancer care technologies and solutions for our clinical
partners around the globe to help them treat millions of patients
each year. With an Intelligent Cancer Care approach, we are
harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 9,200 employees across 70
countries keep the patient and our clinical partners at the center
of our thinking as we power new victories in cancer care.
Because, for cancer patients everywhere, their fight is our
fight. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
Forward-Looking Statements
Except for historical information, this news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements concerning
industry or market outlook, including growth drivers; the company's
future orders, revenues, operating expenses, tax rate, cash flows,
earnings growth or other financial results; and any statements
using the terms "could," "believe," "expect," "promising,"
"outlook," "should," "well-positioned," "will" or similar
statements are forward-looking statements that involve risks and
uncertainties that could cause the company's actual results to
differ materially from those anticipated. Such risks and
uncertainties include our ability to achieve expected synergies
from acquisitions; risks associated with integrating recent
acquisitions; global economic conditions and changes to trends for
cancer treatment regionally; currency exchange rates and tax rates;
the impact of the Tax Cuts and Jobs Act; the impact of the
Affordable Health Care for America Act (including excise taxes on
medical devices) and any further healthcare reforms (including
changes to Medicare and Medicaid), and/or changes in third-party
reimbursement levels; recent and potential future tariffs or a
global trade war; demand for and delays in delivery of the
company's products; the company's ability to develop, commercialize
and deploy new products; the company's ability to meet Food and
Drug Administration (FDA) and other regulatory requirements,
regulations or procedures; changes in regulatory environments;
risks associated with the company providing financing for the
construction and start-up operations of particle therapy centers,
challenges associated with commercializing the company's proton
solutions business; challenges to public tender awards and the loss
of such awards or other orders; the effect of adverse publicity;
the company's reliance on sole or limited-source suppliers; the
company's ability to maintain or increase margins; the impact of
competitive products and pricing; the potential loss of key
distributors or key personnel; challenges related to entering into
new business lines; and the other risks listed from time to time in
the company's filings with the Securities and Exchange Commission,
which by this reference are incorporated herein. The company
assumes no obligation to update or revise the forward-looking
statements in this release because of new information, future
events, or otherwise.
Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-updates-investors-on-proposed-reimbursement-changes-300898631.html
SOURCE Varian